Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy

Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional anal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical rheumatology 2011-01, Vol.30 (1), p.7-13
Hauptverfasser: Nguyen, Sheila, Hojjati, Mehrnaz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 13
container_issue 1
container_start_page 7
container_title Clinical rheumatology
container_volume 30
creator Nguyen, Sheila
Hojjati, Mehrnaz
description Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional analgesics. We performed a comprehensive review of the literature using the PubMed database on treatment modalities available for HOA. We found 52 relevant articles--40 case reports, six case series, two review papers, and four combined case series and review papers. There were no randomized controlled trials reported. We then classified treatments used for HOA into two categories: (1) treatment of primary cause (i.e., resection of tumor, chemotherapy, radiotherapy, treatment of infection, etc.) and (2) symptomatic treatments (i.e., bisphosphonates, octreotide, NSAIDs, vagotomy, etc.). Subsequently, we summarized the main findings for each treatment. Although the clinical diagnosis of HOA has existed for over 100 years, the pathogenesis mechanism has not yet been elucidated, and treatment options for this condition remain experimental. Primary treatment is the most widely reported modality to be efficacious. In cases which primary therapy is not possible, several symptomatic treatment modalities are suggested, with various degree of success. Further research is needed to clarify the pathophysiological mechanism of HOA as to appropriately direct therapy.
doi_str_mv 10.1007/s10067-010-1563-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_822362647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>822362647</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-312db4c50995f18c2ea182b85b23b5abe17b7d10dc14c0685eade0d050f3d7c33</originalsourceid><addsrcrecordid>eNp9kEtv1TAQhS0EoreFH8AGIjZdBWb8iO0lqnhJlRCPri3HmTSp7o2DnYDuv8dXKSCxYOORPd85njmMPUN4hQD6dS5no2tAqFE1otYP2A6lkLW10j5kO9AaaoHWnLHznO8AgBuLj9kZBysaiXbHPn-hHyP9rGJfhTUlmpZqGSj5eaRc9TFVmUKcOp-O1XCcKS0pzsMYqnndH-J0eo55oejTMpSOX4bjE_ao9_tMT-_rBbt59_bb1Yf6-tP7j1dvrusgG1jKWLxrZVBgrerRBE4eDW-NarlolW8Jdas7hC6gDNAYRb4j6EBBLzodhLhgl5vvnOL3lfLiDmMOtN_7ieKaneFcNLyRupAv_yHv4pqmMpwzJTZpFFcFwg0KKeacqHdzGg9lQYfgTmm7LW0Hp3uRuZPx83vjtT1Q90fxO94C8A3IpTXdUvr78_9cX2yi3kfnb9OY3c1XDigALRdKGPEL7u6Ugg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>856348525</pqid></control><display><type>article</type><title>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Nguyen, Sheila ; Hojjati, Mehrnaz</creator><creatorcontrib>Nguyen, Sheila ; Hojjati, Mehrnaz</creatorcontrib><description>Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional analgesics. We performed a comprehensive review of the literature using the PubMed database on treatment modalities available for HOA. We found 52 relevant articles--40 case reports, six case series, two review papers, and four combined case series and review papers. There were no randomized controlled trials reported. We then classified treatments used for HOA into two categories: (1) treatment of primary cause (i.e., resection of tumor, chemotherapy, radiotherapy, treatment of infection, etc.) and (2) symptomatic treatments (i.e., bisphosphonates, octreotide, NSAIDs, vagotomy, etc.). Subsequently, we summarized the main findings for each treatment. Although the clinical diagnosis of HOA has existed for over 100 years, the pathogenesis mechanism has not yet been elucidated, and treatment options for this condition remain experimental. Primary treatment is the most widely reported modality to be efficacious. In cases which primary therapy is not possible, several symptomatic treatment modalities are suggested, with various degree of success. Further research is needed to clarify the pathophysiological mechanism of HOA as to appropriately direct therapy.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-010-1563-7</identifier><identifier>PMID: 20936419</identifier><language>eng</language><publisher>London: London : Springer-Verlag</publisher><subject>Aged ; Antineoplastic Agents - pharmacology ; Bisphosphonates ; Diphosphonates - chemistry ; Female ; Gefetinib ; Humans ; Lung Neoplasms - complications ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; octreotide ; Octreotide - pharmacology ; Osteoarthropathy ; Osteoarthropathy, Secondary Hypertrophic - complications ; Osteoarthropathy, Secondary Hypertrophic - therapy ; Pain ; Quinazolines - pharmacology ; Review Article ; Rheumatology ; Rheumatology - methods ; Secondary hypertrophic ; therapeutics ; Treatment ; Treatment Outcome ; Vagotomy ; Vagotomy - methods</subject><ispartof>Clinical rheumatology, 2011-01, Vol.30 (1), p.7-13</ispartof><rights>Clinical Rheumatology 2010</rights><rights>Clinical Rheumatology 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-312db4c50995f18c2ea182b85b23b5abe17b7d10dc14c0685eade0d050f3d7c33</citedby><cites>FETCH-LOGICAL-c460t-312db4c50995f18c2ea182b85b23b5abe17b7d10dc14c0685eade0d050f3d7c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-010-1563-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-010-1563-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20936419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguyen, Sheila</creatorcontrib><creatorcontrib>Hojjati, Mehrnaz</creatorcontrib><title>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional analgesics. We performed a comprehensive review of the literature using the PubMed database on treatment modalities available for HOA. We found 52 relevant articles--40 case reports, six case series, two review papers, and four combined case series and review papers. There were no randomized controlled trials reported. We then classified treatments used for HOA into two categories: (1) treatment of primary cause (i.e., resection of tumor, chemotherapy, radiotherapy, treatment of infection, etc.) and (2) symptomatic treatments (i.e., bisphosphonates, octreotide, NSAIDs, vagotomy, etc.). Subsequently, we summarized the main findings for each treatment. Although the clinical diagnosis of HOA has existed for over 100 years, the pathogenesis mechanism has not yet been elucidated, and treatment options for this condition remain experimental. Primary treatment is the most widely reported modality to be efficacious. In cases which primary therapy is not possible, several symptomatic treatment modalities are suggested, with various degree of success. Further research is needed to clarify the pathophysiological mechanism of HOA as to appropriately direct therapy.</description><subject>Aged</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Bisphosphonates</subject><subject>Diphosphonates - chemistry</subject><subject>Female</subject><subject>Gefetinib</subject><subject>Humans</subject><subject>Lung Neoplasms - complications</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>octreotide</subject><subject>Octreotide - pharmacology</subject><subject>Osteoarthropathy</subject><subject>Osteoarthropathy, Secondary Hypertrophic - complications</subject><subject>Osteoarthropathy, Secondary Hypertrophic - therapy</subject><subject>Pain</subject><subject>Quinazolines - pharmacology</subject><subject>Review Article</subject><subject>Rheumatology</subject><subject>Rheumatology - methods</subject><subject>Secondary hypertrophic</subject><subject>therapeutics</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><subject>Vagotomy</subject><subject>Vagotomy - methods</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kEtv1TAQhS0EoreFH8AGIjZdBWb8iO0lqnhJlRCPri3HmTSp7o2DnYDuv8dXKSCxYOORPd85njmMPUN4hQD6dS5no2tAqFE1otYP2A6lkLW10j5kO9AaaoHWnLHznO8AgBuLj9kZBysaiXbHPn-hHyP9rGJfhTUlmpZqGSj5eaRc9TFVmUKcOp-O1XCcKS0pzsMYqnndH-J0eo55oejTMpSOX4bjE_ao9_tMT-_rBbt59_bb1Yf6-tP7j1dvrusgG1jKWLxrZVBgrerRBE4eDW-NarlolW8Jdas7hC6gDNAYRb4j6EBBLzodhLhgl5vvnOL3lfLiDmMOtN_7ieKaneFcNLyRupAv_yHv4pqmMpwzJTZpFFcFwg0KKeacqHdzGg9lQYfgTmm7LW0Hp3uRuZPx83vjtT1Q90fxO94C8A3IpTXdUvr78_9cX2yi3kfnb9OY3c1XDigALRdKGPEL7u6Ugg</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Nguyen, Sheila</creator><creator>Hojjati, Mehrnaz</creator><general>London : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</title><author>Nguyen, Sheila ; Hojjati, Mehrnaz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-312db4c50995f18c2ea182b85b23b5abe17b7d10dc14c0685eade0d050f3d7c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Bisphosphonates</topic><topic>Diphosphonates - chemistry</topic><topic>Female</topic><topic>Gefetinib</topic><topic>Humans</topic><topic>Lung Neoplasms - complications</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>octreotide</topic><topic>Octreotide - pharmacology</topic><topic>Osteoarthropathy</topic><topic>Osteoarthropathy, Secondary Hypertrophic - complications</topic><topic>Osteoarthropathy, Secondary Hypertrophic - therapy</topic><topic>Pain</topic><topic>Quinazolines - pharmacology</topic><topic>Review Article</topic><topic>Rheumatology</topic><topic>Rheumatology - methods</topic><topic>Secondary hypertrophic</topic><topic>therapeutics</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><topic>Vagotomy</topic><topic>Vagotomy - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Sheila</creatorcontrib><creatorcontrib>Hojjati, Mehrnaz</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Sheila</au><au>Hojjati, Mehrnaz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>30</volume><issue>1</issue><spage>7</spage><epage>13</epage><pages>7-13</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Hypertrophic osteoarthropathy (HOA) is a disabling condition that may occur secondarily to primary lung cancer. It is characterized by digital clubbing, arthralgia/arthritis, and periostosis of the tubular bones. The pain associated with HOA can be disabling and often refractory to conventional analgesics. We performed a comprehensive review of the literature using the PubMed database on treatment modalities available for HOA. We found 52 relevant articles--40 case reports, six case series, two review papers, and four combined case series and review papers. There were no randomized controlled trials reported. We then classified treatments used for HOA into two categories: (1) treatment of primary cause (i.e., resection of tumor, chemotherapy, radiotherapy, treatment of infection, etc.) and (2) symptomatic treatments (i.e., bisphosphonates, octreotide, NSAIDs, vagotomy, etc.). Subsequently, we summarized the main findings for each treatment. Although the clinical diagnosis of HOA has existed for over 100 years, the pathogenesis mechanism has not yet been elucidated, and treatment options for this condition remain experimental. Primary treatment is the most widely reported modality to be efficacious. In cases which primary therapy is not possible, several symptomatic treatment modalities are suggested, with various degree of success. Further research is needed to clarify the pathophysiological mechanism of HOA as to appropriately direct therapy.</abstract><cop>London</cop><pub>London : Springer-Verlag</pub><pmid>20936419</pmid><doi>10.1007/s10067-010-1563-7</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0770-3198
ispartof Clinical rheumatology, 2011-01, Vol.30 (1), p.7-13
issn 0770-3198
1434-9949
language eng
recordid cdi_proquest_miscellaneous_822362647
source MEDLINE; SpringerLink Journals
subjects Aged
Antineoplastic Agents - pharmacology
Bisphosphonates
Diphosphonates - chemistry
Female
Gefetinib
Humans
Lung Neoplasms - complications
Male
Medicine
Medicine & Public Health
Middle Aged
octreotide
Octreotide - pharmacology
Osteoarthropathy
Osteoarthropathy, Secondary Hypertrophic - complications
Osteoarthropathy, Secondary Hypertrophic - therapy
Pain
Quinazolines - pharmacology
Review Article
Rheumatology
Rheumatology - methods
Secondary hypertrophic
therapeutics
Treatment
Treatment Outcome
Vagotomy
Vagotomy - methods
title Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T07%3A44%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20current%20therapies%20for%20secondary%20hypertrophic%20pulmonary%20osteoarthropathy&rft.jtitle=Clinical%20rheumatology&rft.au=Nguyen,%20Sheila&rft.date=2011-01-01&rft.volume=30&rft.issue=1&rft.spage=7&rft.epage=13&rft.pages=7-13&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-010-1563-7&rft_dat=%3Cproquest_cross%3E822362647%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=856348525&rft_id=info:pmid/20936419&rfr_iscdi=true